|
CAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.06303895978044E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.05489974930617E-10 |
| Normal-vs-Stage2 |
1.023750E-03 |
| Normal-vs-Stage3 |
1.88150051094738E-10 |
| Normal-vs-Stage4 |
1.44995127016045E-13 |
| Stage1-vs-Stage2 |
1.182390E-01 |
| Stage1-vs-Stage3 |
4.131600E-02 |
| Stage1-vs-Stage4 |
1.227190E-04 |
| Stage2-vs-Stage3 |
1.061760E-02 |
| Stage2-vs-Stage4 |
2.023900E-04 |
| Stage3-vs-Stage4 |
1.197400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.72066830070617E-13 |
| Normal-vs-AfricanAmerican |
1.199290E-03 |
| Normal-vs-Asian |
1.73629999999925E-06 |
| Caucasian-vs-AfricanAmerican |
5.111600E-01 |
| Caucasian-vs-Asian |
3.242400E-01 |
| AfricanAmerican-vs-Asian |
9.208000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.01499997085375E-09 |
| Normal-vs-Female |
9.80304726283521E-12 |
| Male-vs-Female |
7.054800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.98420000430133E-08 |
| Normal-vs-Age(41-60Yrs) |
2.93280000285279E-09 |
| Normal-vs-Age(61-80Yrs) |
1.69775304925679E-12 |
| Normal-vs-Age(81-100Yrs) |
1.257810E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.453600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.681800E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.357400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.360200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.103000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.205400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.34829999679454E-08 |
| Classical-VS-Follicular |
1.254100E-02 |
| Classical-VS-Other |
2.563200E-01 |
| Classical-VS-Normal |
8.18911605193762E-12 |
| Tall-VS-Follicular |
5.56940049634136E-10 |
| Tall-VS-Other |
1.393280E-04 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
8.888000E-01 |
| Follicular-VS-Normal |
5.418000E-04 |
| Other-VS-Normal |
1.139650E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.68840008219729E-10 |
| Normal-vs-N1 |
4.98439955975982E-10 |
| N0-vs-N1 |
6.417900E-02 |
|
|
